Organon

Organon & Co. is a global pharmaceutical company based in Jersey City, New Jersey, with a history that began in 1923 in the Netherlands. The company specializes in women's health, biosimilars, and established medicines, having been spun off from Merck & Co. in 2021. Organon operates in over 140 markets and employs around 9,500 people, with a leadership team that emphasizes diversity and inclusion. The company's offerings are structured around three main areas. Women's health, which accounts for about 27% of revenue, includes contraceptives like Nexplanon, fertility treatments such as Puregon, and hormone replacement therapies. Biosimilars make up roughly 8% of revenue, featuring products like Hadlima, which provides affordable options for oncology and immunology. Established brands represent about 64% of revenue, encompassing a variety of trusted medicines in cardiovascular health, dermatology, pain management, and more. Organon is committed to improving health outcomes for women globally and supports policies that enhance access to healthcare. The company maintains a strong focus on research and innovation, contributing to advancements in medical science.